(Redirected from IPH2201)
Mechanism of actionEdit
- A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies
- IPH2201 studies
- First Clinical Data For Monalizumab As A Single Agent In Cancer Patients Show Favorable Safety Profile
- AstraZeneca Inks $1.8B in Immuno-Oncology Deals as Q1 Profit Dips
- "monalizumab". Archived from the original on 2016-12-20. Retrieved 2016-12-09.
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|